Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease  

作　　者：Bei Yue Zhi-Lun Yu Cheng Lv Xiao-Long Geng Zheng-Tao Wang Wei Dou 

机构地区：[1]Laboratory of Standardization of Chinese Medicines,Shanghai Key Laboratory of Compound Chinese Medicines,and the SATCM key Laboratory of New Resources and Quality Evaluation of Chinese Medicines,Institute of Chinese Materia Medica,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China

出　　处：《World Journal of Gastroenterology》2020年第30期4378-4393,共16页世界胃肠病学杂志（英文版）

基　　金：Supported by National Natural Science Foundation of China,No.81273572 and No.81530096;the Natural Science Foundation of Shanghai,No.17ZR1427800.

摘　　要：The rapid development of metagenomics,metabolomics,and metatranscriptomics provides novel insights into the intestinal microbiota factors linked to inflammatory bowel disease(IBD).Multiple microorganisms play a role in intestinal health;these include bacteria,fungi,and viruses that exist in a dynamic balance to maintain mucosal homeostasis.Perturbations in the intestinal microbiota disrupt mucosal homeostasis and are closely related to IBD in humans and colitis in mice.Therefore,preventing or correcting the imbalance of microbiota may serve as a novel prevention or treatment strategy for IBD.We review the most recent evidence for direct or indirect interventions targeting intestinal microbiota for treatment of IBD in order to overcome the current limitations of IBD therapies and shed light on personalized treatment options.

关 键 词：Inflammatory bowel disease Pro/Prebiotics Fecal microbiota transplantation Herbal medicines Clinical application 

分 类 号：R574[医药卫生—消化系统]